International Journal of Trend in Scientific Research and Development (IJTSRD)
Volume: 3 | Issue: 3 | Mar-Apr 2019 Available Online: www.ijtsrd.com e-ISSN:
ISSN: 2456 - 6470
An Overview on Tuberculosis (TB)
Prakash Teron1, Rahul Singh Kushwaha1, Atul Tiwari2, Kaushal K.. Chandrul3
1Pharmacy
Graduate, 2Associate Professor & Researcher, 3Faculty of Research
esearch and Development
1,2,3Mewar University, Chittorgarh, Rajasthan, India
How to cite this paper: Prakash Teron
| Rahul Singh Kushwaha | Atul Tiwari |
Kaushal K. Chandrul "An Overview on
Tuberculosis (TB)" Published in
International Journal of Trend in
Scientific Research and Development
(ijtsrd), ISSN: 24566470, Volume-3 |
Issue-3, April 2019,
pp.1820-1825, URL:
https://www.ijtsrd.
com/papers/ijtsrd2
IJTSRD23543
3543.pdf
Copyright © 2019 by author(s) and
International Journal of Trend in
Scientific Research and Development
Journal. This is an Open Access article
distributed under
the terms of the
Creative Commons
Attribution License (CC BY 4.0)
(http://creativecommons.org/licenses
/by/4.0)
ABSTRACT
Tuberculosis (TB) stays one of the deadliest irresistible ailments in charge of
millions of passing’s every year over the world. In this paper we present a
general review of TB including the pathogenesis,
pathogenesis, analysis, and treatment
rules. In readiness of this review, we scanned PubMed for pertinent articles
on TB. Furthermore, we looked through the sites of global establishments like
the World Health Organization (WHO) and the US Centers for Disease contro
control
and Prevention (CDC) for related reports and clinical rules. This paper has
been composed with the goal to offer general training to wellbeing experts,
arrangement producers, patients and the general population.
KEYWORDS: Tuberculosis(TB); Global epidemiology; Pathogenesis of TB; Risk
factor drug resistant TB; Diagnosis; Prevention; Treatment of TB
INTRODUCTION
Tuberculosis (TB) is one of the principal old
old-fashioned
sicknesses of humankind and has co-developed
developed with
individuals for various a large numbers of quite a while or
perhaps for a couple of million years [1]. One out of three
individuals over the world addressing
ressing 2-3
2
billion
individuals are known to be spoiled with Mycobacterium
Tuberculosis (M. Tuberculosis) of which 5
5-15% are
probably going to make dynamic TB ailment in the midst
of their lifetime[2]. The most prepared realized nuclear
demonstrate of TB was
as perceived in a fossil of an ended
bison (Pleistocene wild ox), which was radiocarbon dated
at 17,870±230 years [3]. Disregarding the way that as
ahead of schedule as 1689, it was developed by Dr.
Richard Morton that the aspiratory shape was connected
with
th "tubercles," because of the variety of its symptoms,
TB was not recognized as a solitary[4]
Around the world, in 2015, there were 10.4 million new
instances of TB and 1.8 million passing’s inferable from
the malady [5]. Through escalated look into, progress in
the arrangement of coordinated patient consideration and
execution of supportable wellbeing
eing approaches, the World
Health Organization (WHO) has set an objective of
diminishing the TB frequency rate by 90% and the
quantity of TB-related
related passing’s by 95% continuously
2035, as illustrated in its 'End TB Strategy' [6]. A definitive
point is to accomplish
ccomplish worldwide destruction of TB. In any
case, to accomplish these aspirations, a few difficulties
relating to TB the executives should be survived.
Notwithstanding tending to the weight of malady brought
about by medication touchy TB, it is critical
critic to handle the
expanding risk of multidrug-safe
safe (MDR) TB, characterized
as TB brought about by M. tuberculosis disconnects that
are impervious to both rifampicin and isoniazid [5
[5]. Since
the safe structure in sound people dividers off the
causative infinitesimal
itesimal life forms, TB malady in strong
people is as often as possible asymptomatic. This
bacterium lives and copies in the macrophages,
accordingly avoiding the typical opposition system in the
patient's serum. Sullying with TB can result in two stages:
Latent Tuberculosis Infection(LTBI) or tuberculosis
disorder. Accepting left untreated, the death rate with this
malady is over half. For this survey article, information
accessible at the official sites of World Health
Organization(WHO); from the Ministry of Health,
Government of India; through PubMed focal and Google
scholar web crawlers were broadly counseled This article
gives a report on the clinical way to deal with overseeing
drug-touchy,
touchy, sedate safe and inert TB. The worldwide the
study of disease transmission
ransmission of the sickness, clinical
introduction and ways to deal with the board are talked
about. Future research and clinical needs are considered.
We should keep on directing examination to streamline
conveyance of viable intercessions, just as grow n
new
instruments that can expand
xpand intruding on tuberculosis
transmission.
International Journal of Trend in Scientific Research and Development (IJTSRD) @ www.ijtsrd.com eISSN: 2456-6470
Anticipated quickening in the decay of worldwide
tuberculosis frequency rates to target levels. From WHO
END TB Strategy[7].
The resistant framework in sound individuals dividers off
the causative microscopic organisms, TB disease in solid
individuals is regularly asymptomatic. This bacterium
lives and increases in the macrophages, consequently
dodging the regular protection framework in the patient's
serum. Contamination with TB can result in two phases:
asymptomatic idle tuberculosis contamination (LTBI) or
tuberculosis malady. Whenever left untreated, the death
rate with this ailment is over half. For this survey article,
information accessible at the official sites of World
HealthOrganisation (WHO); from the Ministry of Health,
Government of India; through PubMed focal and Google
scholar® web search tools were broadly counseled.
GLOBAL EPIDEMIOLOGY
Careful appraisals of TB rate rely upon generous national
perception segments that hope to address issues of underreporting. TB rate per country may be surveyed using
distinctive systems: case see data may be united with ace
assessments on the conceivable dimension of underspecifying and under-discovering; high-compensation
countries may apply a change factor to their declared
notice number to speak to under-uncovering and underinvestigation; recurrence may be assessed using results
from TB inescapability ponders [1].
There was a 1.5% decrease in TB rate all around some
place in the scope of 2014 and 2015. In 2015, the country
with the most amazing load of TB illness was India, with a
normal hard and fast TB recurrence of 2.84 million
(powerlessness between time 1.47– 4.65 million). Of the
10.4 million scene TB cases that year, 60% of cases were
represented from the going with six countries in lessening
solicitation of event: India, Indonesia, China, Nigeria,
Pakistan and South Africa. By region, 61% of cases were in
Asia; 26% in Africa; 7% in the Eastern Mediterranean; 3%
in Europe; and 3% in the Americas. HIV coinfection was
represented in 11% of cases and was most conspicuous in
countries in southern Africa [1].
Around a similar time, there were 1.4 million passings
from TB among HIV-opposite people (19 for each 100,000
masses), of which 84% occurred in Africa and Southeast
Asia. There were a further 0.39 million passings from TB
among HIV-constructive individuals. India and Nigeria
spoke to 43% of the full scale number of TB passings
among HIV-critical and HIV-useful people joined. All
landmasses and there has been a 34% reduction in the TB
demise rate some place in the scope of 2000 and 2015 [1].
MDR TB and rifampicin-safe (RR) TB spoke to 3.9% of new
TB cases and 21% of as of late treated TB cases in 2015.
MDR and RR TB spoke to 580,000 occurrences of scene TB
cases and 250,000 passings all around. China, India and
Russia spoke to 45% of the overall outright MDR and RR
TB case inconvenience [1]
PATHOGENESIS OF TB
TB is an airborne bacterial infection caused by M.
Tuberculosis which affects any part of the body and most
commonly the lungs[8]. Tuberculosis is transmitted by
inhalation of aerosolised droplets (1–5µm in diameter)
from an infected person coughing, sneezing or talking.
Droplets are deposited in the alveoli, where the bacteria
are ingested by alveolar macrophages, resulting in a series
of host-pathogen interactions. Thirty per cent of exposed
individuals become infected. In 90 per cent of infected
people, the infection is contained by host responses and
becomes latent. The remaining 10 per cent develop
progressive primary tuberculosis.
Mycobacteria are intracellular pathogens that can survive
and multiply within macrophages. During primary
infection, infected macrophages are carried by the
lymphatic system to regional lymph nodes, but may
disseminate throughout the body via the bloodstream.
This may result in seeding to extra-pulmonary sites, where
the infection can lie dormant until it is reactivated, or
disseminated active infection. Five per cent of individuals
with latent TB will develop active disease within two
years, and another five per cent will develop it at some
point in their lives[9]. The small unaffected proportion
multiplies within the macrophages and is released upon
death of the macrophages. Live released tubercle bacilli
spread via the bloodstream or lymphatic channels to any
part of the body tissues or organs in addition to highly
susceptible areas of TB infection such as the lungs, larynx,
lymph nodes, spine, bone or kidneys [10]. In about 2 to 8
weeks[11]. An immune response is triggered which allows
white blood cells to encapsulate or destroy majority of the
tubercle bacilli. Theencapsulation by the white blood cells
results in a barrier around the tubercle bacilli forming a
granuloma [12]. On the other hand, if the immune system
fails to keep the tubercle bacilli under control, rapid
multiplication of the bacilli ensues which leads to a
progression from LTBI to a case of TB. The time for
progression to TB may be soon after LTBI or longer
occurring after many years. A TB case is highly infectious
International Journal of Trend in Scientific Research and Development (IJTSRD) @ www.ijtsrd.com eISSN: 2456-6470
DIAGNOSIS
Analysis of TB needs to assess clinical history,
microbiological results and radiological discoveries.
Clinical history and risk factors for TB
Clinical indications of TB sickness rely on the site of TB
contamination. Traditionally, aspiratory TB is described
by a past filled with constant hack, sputum generation,
haemoptysis, fever, night sweats and weight loss[14]. On
account of additional pneumonic TB (i.e., TB creating
outside the lungs), showing side effects will frequently be
managed by the piece of the body influenced, albeit, a few
indications, for example, loss of craving, night sweat and
fever might be more general[15].
 For TB meningitis for example, patients may give
cerebral pain or confusion [16] Central sensory
system TB may show as TB meningitis, tuberculomas
or TB mind abscesses [17].
 TB lymphadenitis is described by effortless, dynamic
lymph hub swelling [18]. Cervical chain lymph hubs
are the commonest site [19].
 Whereas patients encountering TB of the spine may
give extreme back agony [20,21].
 TB peritonitis is portrayed most normally by stomach
torment, fever and weight reduction. Other
gastrointestinal indications incorporate loose bowels,
ascites, hepatomegaly and splenomegaly [22];
 Genitourinary TB may result in dysuria, haematuria,
flank torment, pelvic provocative ailment and
epidydimal masses relying upon the particular site of
contamination [23];
 TB pericarditis is uncommon, described by side effects
of chest torment, hack and dyspnoea and clinical
discoveries
incorporate
fever,
tachycardia,
cardiomegaly and a pericardial rub [24].
This is then trailed by physical examination which
assesses the person's complete condition and illuminates
symptomatic techniques. In any case, the physical
examination isn't expected to affirm or discount TB.
Testing for M. Tuberculosis is accomplished either through
skin or blood tests. The skin test is known as Mantoux
tuberculin test which is started by infusing a standard
portion of tuberculin liquid into the skin of the lower part
of the arm [25]
RISK FACTOR FOR DRUG RESISTANT TB
From a microbiological perspective, MDR-TB and XDR-TB
are brought about by hereditary transformation of the M.
Tuberculosis which renders hostile to TB specialists
incapable against the freak tubercle bacilli [26]. Be that as
it may, Caminero [27] proposes two classes of hazard
factors for medication safe tuberculosis. The primary
classification, he depicts as 'those encouraging the choice
of obstruction in the network' and the second as 'explicit
conditions that seem to build some patient's
defencelessness to opposition' [27].
Factors facilitating the selection of resistance in the
community
The major contributing component to the advancement of
medication safe TB in networks is poor National
Tuberculosis Programs (NTP). This might be because of
absence of subsidizing to encourage preparing of staff and
execution of regulatory controls towards patient
administration. Another contributing element might be
absence of DOTS (Directly Observed Therapy Short
Course) system usage or its productivity where they are
actualized which may result in insufficient or absence of
treatment monitoring[27].
Insufficiency in medication supply Characterized by
incessant medication deficiencies, unacceptable Quality of
accessible medications or improper routine or Dosage can
likewise add to expanding danger of safe Tuberculosis. In
an overview on isoniazid supply led By the United States'
National Tuberculosis Controllers Association (NTCA) in
January, 2013, ends on Patient consideration obstructions
were made about 79% of wellbeing Facilities announced
acquirement troubles of isoniazid Within the period of
December, 2012 alone[28]. Then again, 15% revealed
stopped supply of isoniazid within that month. This thus
prompted 69% of thehealth offices exchanging providers
of isoniazid whiles 68% deferred treatment of LTBI and
88% changing to Alternative routine. Such irregularities
increment odds of medication safe TB just as transmission.
Patients can Also add to expanding the danger of
medication safe Tuberculosis. This is made conceivable
when patients getting Treatment don't hold fast to
treatment routine because of Lack of cash to bear the cost
of treatment, social derision or Treatment inconvenience
by occurrence of unfavorable occasions [29].
Specific conditions which increase some patients’
Vulnerability to resistance
Caminero [27] further classifies the dangers of procuring
Drug-safe TB into three arrangements of defenseless
gatherings. The First gathering are patients who
dependent on bacteriological outcomes Are delegated
being at high danger of medication safe TB. These patients
have a place with the Category II TB treatment Failures
including 2 months of isoniazid, rifampicin, Pyrazinamide,
Ethambutol and streptomycin, trailed By multi month of
isoniazid, rifampicin, pyrazinamide and Ethambutol and a
5-month consistent period of isoniazid, Rifampicin and
Ethambutol. Other high hazard patients for Drug-safe TB
are those grouped under Category I and II who have
flopped on two events, rifampicin Containing routine
[29,30] and furthermore territories which don't Have
access to DST labs. The second gathering of Patients is the
individuals who are at high danger of medication safe TB
Based on close contact with medication safe TB patients or
patients named Category I TB routine disappointment.
Close contacts with MDR-TB cases have been accounted
for to have an alternate safe strain from the file case [29,
31]. Because of this high danger of obtaining MDR-TB,
suspected Close contacts with MDR-TB cases are started
comparative TB Regimen to the file case without DST
results and subsequently altered when DST results are
accessible. For patients with Category I treatment
disappointment, the danger Of MDR-TB is variable from
among nations. Under this Condition, a few nations record
low MDR-TB rate, for example, Malawi [32] and Benin
[33]. Certain drugs, for example, corticosteroids and
infliximab (an enemy of αTNF monoclonal counter acting
agent), are winding up progressively vital hazard factors,
particularly in the created world.[34] Hereditary
helplessness additionally exists,[35] for which the general
significance remains undefined.[34]
@ IJTSRD | Unique Paper ID - IJTSRD23543 | Volume – 3 | Issue – 3 | Mar-Apr 2019
Page: 1822
International Journal of Trend in Scientific Research and Development (IJTSRD) @ www.ijtsrd.com eISSN: 2456-6470
Tuberculosis prevention poster from the United States, c.
1940
One of the real endeavours of WHO and its accomplices is
to Ensure preventive measures toward stopping the
expanding Prevalence of medication safe TB [35]. Inside
various Countries, there is the requirement for essential
research to Determine factors adding to treatment default
Within various nations, there is the requirement for
essential research to decide factors adding to treatment
default [35].The World Health Organization has made
some progress with improved treatment regimens, and a
little abatement in the event that numbers.[34] The US
Preventive Services Task Force (USPSTF) suggests
screening individuals who are at high hazard for idle
tuberculosis with either tuberculin skin tests or
interferon-gamma discharge assays[36].
Another method for forestalling drug safe TB is to improve
adherence of patients to treatment. This can be
accomplished by creating understanding consideration
plans went for isolated treatment alternatives (i.e.,
inpatient, outpatient or network based treatment) just as
diminishing pill trouble in TB routine methodology. A
grouped randomized controlled preliminary led by Thiam
et al. [37] in Senegal to survey new imperative proposition
on improving patient adherence to TB treatment realized
88% treatment accomplishment in the intervention
bundle differentiated and 76% in the control gathering. In
addition, tolerant default rate was diminished to 5.5% in
the intervention group instead of 16.8% in the control
gathering. A bit of the interventions investigated were
apportioning greater chance to controlling what's more,
correspondence
between
human
administrations
providers and TB patients, decentralizing treatment
outlets to stations nearer to patients, choice of DOT
supporter by patient and fortifying supervision works out.
Vaccines
The only available vaccine as of 2011 is Bacillus
CalmetteGuerin (BCG).[38]In children it decreases the risk
of getting the infection by 20% and the risk of infection
turning into active disease by nearly 60%.[39]
It is the most generally utilized immunization around the
world, with over 90% of all youngsters being
vaccinated.[40] The resistance it instigates diminishes
after around ten years.[40] As tuberculosis is remarkable
in the majority of Canada, the United Kingdom, and the
United States, BCG is regulated to just those individuals at
high risk.[41,42,43] Part of the thinking against the
utilization of the antibody is that it makes the tuberculin
skin test dishonestly positive, decreasing the test's
helpfulness as a screening tool.[43] various new
Checking treatment routine is cantered around following
Record of treatment reaction and taking suitable Actions,
overseeing interference of treatment, companion
Evaluation of treatment results and the recognition and
Management of medication incited unfriendly responses
[44]. Record Of treatment reaction is accomplished by
performing sputum Smear microscopy and culture at
customary interims and the Regimen acclimated to suit
the proper weakness Pattern [45]. Furthermore, month to
month estimation of Patient's weight is prescribed to
educate weight Depended portion changes [46].
Treatment intrusions by defaulting patients or HIV cocontamination are recorded and patients returning after
default are tried again for Drug defenselessness [44].
Accomplice assessment of treatment Outcomes helps in
getting to the treatment achievement of a specific decision
of routine just as the adequacy of the medications
included. Antagonistic responses are intently checked By
wellbeing work force through perceptions and record of
Signs and indications [47]. Patients are additionally
informed on likely Symptoms of medication instigated
unfriendly impacts to energize Reporting of their
occurrence. Fix is accomplished for TB Treatment because
of an aggregate exertion of the patient And TB program
staff. All things considered, tolerant supervision and
backing through Directly Observed Treatment Short
course (DOTS). Under DOTS, the TB program staffs watch
the admission of each portion on the treatment routine
guaranteeing the patient takes the correct medication with
the right dosages and at the fitting interims [48]. Specks
additionally upgrade correspondence among patient and
staff which opens open doors for further TB instruction,
early distinguishing proof of non-adherence and
unfavourable responses [44, 48, 49].
CONCLUSION
Tuberculosis stays a standout amongst the most fatal
irresistible Diseases and has guaranteed a huge number of
lives for a long time. While noteworthy advancement has
been made towards controlling the worldwide weight of
TB over the previous decade, more endeavours are as yet
required. Developing issues, for example, multi Drugobstruction takes steps to return the advancement made
Regarding TB care and control. The information base for
TB remains a quickly extending zone and worldwide rules
are ceaselessly being refined for example to consolidate
new Anti-tubercular medications to handle issues of
obstruction. Wellbeing Professionals, strategy producers,
patients and the overall population need to stay up with
the latest with current patterns in TB Management and
control. This will be basic for productive Adoption of
worldwide rules to nation level circumstance, especially
thinking about issues, for example, ailment Burden,
wellbeing framework structures and accessible assets.
REFERENCE
[1] Hirsh AE, Tsolaki AG, DeRiemer K, Feldman MW,
Small PM. Stable association between strains
of Mycobacterium tuberculosis and their human host
populations. Proc Natl Acad Sci USA. 2004;101:4871–
6.[PMC free article] [PubMed] [Google Scholar]
[2]
World
Health
Organisation.
2015
Global
Tuberculosis Report. Geneva, Switzerland: WHO,
2015.
International Journal of Trend in Scientific Research and Development (IJTSRD) @ www.ijtsrd.com eISSN: 2456-6470
[3] Rothschild BM, Martin LD, Lev G, Bercovier H, BarGal GK, Greenblatt CL, et al. Mycobacterium
tuberculosis Complex DNA from an Extinct Bison
Dated 17,000 Years before the Present. Clin Infec
Dis. 2001; 33:305–11. [PubMed] [Google Scholar
[4] News-medical.net [Internet]. History of Tuberculosis.
[Last cited on 2010 Oct 15]. Available
from: http://www.news-medical.net/health/Historyof-Tuberculosis.aspx .
[5] World
Health
Organisation.
WHO
Global
Tuberculosis Report 2016. WHO, 2016. Accessed on
1st
July
2017.
Available
online:
http://www.who.int/tb/publications/global_report/
en/
[6] World Health Organisation. The End TB Strategy.
Global strategy and targets for tuberculosis
prevention, care and control after 2015. WHO, 2016.
Accessed on 1st July 2017. Available online:
http://www.who.int/tb/post2015_TBstrategy.pdf?u
a=1
[7] Barnagarwala T. TB hospital staff live under shadow
of dreaded disease. The Indian Express. Uttar
Pradesh, India: IE Online Media Services, 2014
[8] Dye C, Floyd K. Tuberculosis. In: Jamison DT, Breman
JG, Measham AR, et al. editors. Disease Control
Priorities in Developing Countries, 2nd Ed. New York:
Oxford University Press, 2006.
[9] Collins HL, Kaufmann SHE. Prospects for better
tuberculosis vaccines. Lancet Infectious Diseases
2001; 1:21–8.
[10] Smith I. Mycobacterium tuberculosis pathogenesis
and molecular determinants of virulence. Cline
Microbial Rev. 2003; 16:463-96.
[11] Haley CA. Prevention of Tuberculosis: TB Screening,
Diagnosis of Latent Tuberculosis Infection and
Preventive
Therapy.
South-eastern
National
Tuberculosis Centre, 2013 [August 12
2016].
Available
online:
https://sntc.medicine.ufl.edu/Files/Haiti/Module%2
05%20Diagnosis%20and%20Treatment%20of%20L
TBI%20ENGLISH.pdf
[12] Schluger NW. The pathogenesis of tuberculosis: the
first one hundred (and twenty-three) years. Am J
Respir Cell Mol Biol 2005; 32:251-6.
[13] CDC. Chapter 2: Transmission and Pathogenesis of
Tuberculosis [August 15 2016]. Available online:
https://www.cdc.gov/tb/education/corecurr/pdf/ch
apter2.pdf
[14] Lawn SD, Zumla AI. Tuberculosis. Lancet 2011;
378:57-72. [Crossref] [PubMed]
[15] Lee JY. Diagnosis and treatment of extra pulmonary
tuberculosis. Tuberc Respir Dis (Seoul) 2015; 78:4755.
[16] CDC. Chapter 4: Diagnosis of Tuberculosis Disease
[August
15
2016].
Available
online:
https://www.cdc.gov/tb/education/corecurr/pdf/ch
apter4.pdf
[17] Rock RB, Olin M, Baker CA, et al. Central nervous
system tuberculosis: pathogenesis and clinical
aspects. Clin Microbiol Rev 2008; 21:243-61.
[Crossref] [PubMed]
[18] Artenstein AW, Kim JH, Williams WJ, et al. Isolated
peripheral tuberculous lymphadenitis in adults:
current clinical and diagnostic issues. Clin Infect Dis
1995; 20:876-82. [Crossref] [PubMed]
[19] Polesky A, Grove W, Bhatia G. Peripheral tuberculous
lymphadenitis: epidemiology, diagnosis, treatment,
and outcome. Medicine (Baltimore) 2005; 84:350-62.
[Crossref] [PubMed]
[20] Cormican L, Hammal R, Messenger J, et al. Current
difficulties in the diagnosis and management of
spinal tuberculosis. Postgrad Med J 2006; 82:46-51.
[21] Rasouli MR, Mirkoohi M, Vaccaro AR, et al. Spinal
tuberculosis: diagnosis and management. Asian Spine
J 2012; 6:294-308.
[22] Sanai FM, Bzeizi KI. Systematic review: tuberculous
peritonitis--presenting features, diagnostic strategies
and treatment. Aliment Pharmacology Ther 2005;
22:685-700. [Crossref] [PubMed]
[23] Kapoor R, Ansari MS, Mandhani A, et al. Clinical
presentation and diagnostic approach in cases of
genitourinary tuberculosis. Indian J Urol 2008;
24:401-5. [Crossref] [PubMed]
[24] Trautner
BW,
Darouiche
RO. Tuberculous
pericarditis: optimal diagnosis and management. Clin
Infect Dis 2001; 33:954-61. [Crossref] [PubMed]
[25] CDC. Testing for TB infection 2016 [August 12 2016].
Available
online:
http://www.cdc.gov/tb/topic/testing/tbtesttypes.ht
m
[26] Migliori GB, Centis R, Lange C, et al. Emerging
epidemic Of drug-resistant tuberculosis in Europe,
Russia, China, South America and Asia: current status
and global Perspectives. Curr Opin Pulm Med 2010;
16:171-9.
[27] Caminero JA. Multidrug-resistant tuberculosis:
Epidemiology, risk factors and case finding. Int J
Tuberc Lung Dis 2010; 14:382-90.
[28] World Health Organization. Guidelines for the
Programmatic management of drug resistant
tuberculosis 2011 Update. Geneva, Switzerland:
WHO, 2011.
[29] Centers for Disease Control and Prevention (CDC).
Impact of a shortage of first-line anti tuberculosis
Medication on tuberculosis control – United States,
2012-2013. MMWR Morb Mortal Wkly Rep 2013;
62:398-400.
[30] Suarez PG, Floyd K, Portocarrero J, et al. Feasibility
And cost-effectiveness of standardised second-line
drug Treatment for chronic tuberculosis patients: a
national Cohort study in Peru. Lancet 2002;
359:1980-9.
[31] Kritski AL, Marques MJ, Rabahi MF, et al.
Transmission Of tuberculosis to close contacts of
patients with Multidrug-resistant tuberculosis. Am J
Respir Crit Care Med 1996; 153:331-5.
@ IJTSRD | Unique Paper ID - IJTSRD23543 | Volume – 3 | Issue – 3 | Mar-Apr 2019
Page: 1824
International Journal of Trend in Scientific Research and Development (IJTSRD) @ www.ijtsrd.com eISSN: 2456-6470
[32] Harries AD, Nyirenda TE, Kemp JR, et al. Management
and outcome of tuberculosis patients who fail
treatment under routine programme conditions in
Malawi. Int J Tuberc Lung Dis 2003; 7:1040-4.
[40] World Health Organization. "Global tuberculosis
control–surveillance, planning, financing WHO Report
2006". Archived from the original on 12 December
2006. Retrieved 13 October 2006.
[33] Trébucq A, Anagonou S, Gninafon M, et al. Prevalence
Of
primary
and
acquired
resistance
of
Mycobacterium Tuberculosis to anti tuberculosis
drugs in Benin after 12 Years of short-course
chemotherapy. Int J Tuberc Lung Dis 2010;14
[41]
Chaisson RE, Martinson NA (March 2008).
"Tuberculosis in Africa – combating an HIV-driven
crisis". The
New
England
Journal
of
Medicine. 358 (11):
1089–
92. Doi:10.1056/NEJMp0800809. PMID 18337598.
[34] Lawn
SD,
Zumla
AI
(July
"Tuberculosis". Lancet. 378 (9785):
72. Doi:10.1016/S0140-6736(10)621733. PMID 21420161
[42]
Griffith DE, Kerr CM (August 1996). "Tuberculosis:
disease of the past, disease of the present". Journal of
Perianesthesia
Nursing. 11 (4):240–
45. Doi:10.1016/S1089-9472(96)800232. PMID 8964016.
[43]
"Targeted tuberculin testing and treatment of latent
tuberculosis
infection.
American
Thoracic
Society". MMWR.
Recommendations
and
Reports. 49 (RR-6):
1–51.
June
2000. PMID 10881762. Archived from the original on
17 December 2004.
[35]
2011).
57–
Möller M, Hoal EG (March 2010). "Current findings,
challenges and novel approaches in human genetic
susceptibility to tuberculosis". Tuberculosis. 90 (2):
71–83. Doi:10.1016/j.tube.2010.02.002. PMID
[36] Bibbins-Domingo K, Grossman DC, Curry SJ, Bauman
L, Davidson KW,Epling JW, García FA, Herzstein J,
Kemper AR, Krist AH, Kurth AE, Landefeld CS,
Mangione CM, Phillips WR, Phipps MG, Pignone MP
(September
2016).
"Screening
for
Latent
Tuberculosis Infection in Adults: US Preventive
Services
Task
Force
Recommendation
Statement". JAMA. 316 (9):
96269. Doi:10.1001/jama.2016.11046. PMID
[37] Thiam S, LeFevre AM, Hane F, et al. Effectiveness of a
strategy to improve adherence to tuberculosis
treatment in a resource-poor setting: a cluster
randomized controlled trial. JAMA 2007; 297:380-6.
[38] McShane H (October 2011). "Tuberculosis vaccines:
beyond
bacilli
Calmette-Guerin". Philosophical
Transactions of the Royal Society of London. Series B,
Biological Sciences. 366 (1579):
278289. Doi:10.1098/rstb.2011.0097. PMC 3146779. PMI
D 21893541
[39] Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S,
Habermann S, Snell L, Mangtani P, Adetifa I, Lalvani
A, Abubakar I (August 2014). "Effect of BCG
vaccination against Mycobacterium tuberculosis
infection in children: systematic reviewandmetaanalysis". BMJ. 349:
g4643. Doi:10.1136/bmj.g4643. PMC 4122754. PMID
[44] World
Health
Organization.
Treatment
of
Tuberculosis, Fourth Edition. Geneva, Switzerland:
WHO, 2010. World Health Organization. WHO
Treatment guidelines for drug-resistant tuberculosis;
2016 Update. Geneva, Switzerland: WHO, 2016.
[45] TB CARE I. International Standards for Tuberculosis
Care, Edition 3. The Hague: TB CARE I, 2014.
[46] Warmelink I, ten Hacken NH, van der Werf TS, et al.
Weight loss during tuberculosis treatment is an
important
Risk
factor
for
drug-induced
hepatotoxicity. Br J Nutr 2011; 105:400-8.
[47] Lorent N, Sebatunzi O, Mukeshimana G, et al.
Incidence and risk factors of serious adverse events
during antituberculous treatment in Rwanda: a
prospective cohort study. PLoS One 2011; 6:e19566.
[48] Davies PD. The role of DOTS in tuberculosis
treatment and control. Am J Respir Med 2003; 2:2039?
[49] Sandhu GK. Tuberculosis: current situation,
challenges and overview of its control programs in
India. J Glob Infect Dis 2011; 3:143-50.
@ IJTSRD | Unique Paper ID - IJTSRD23543 | Volume – 3 | Issue – 3 | Mar-Apr 2019
Page: 1825